Articles tagged with Melanoma
A team of McMaster University graduates has developed a skin cancer detection device called The sKan, which creates a thermal map on the region of interest on the skin. The device is made up of 16 temperature-sensitive components and assists physicians in detecting melanoma by providing quantitative information about skin spots.
A study found circulating tumor cells (CTCs) associated with relapse in stage IV melanoma patients, suggesting a potential predictor for high-risk disease progression via liquid biopsy. CTCs were detected in approximately 40% of advanced stage melanoma patients and linked to faster relapse rates.
A University of Colorado Cancer Center study finds a genetic change called ALK-fusion in a patient sample of a melanoma subtype called mucosal melanoma. Treated with FDA-approved drugs, the tumor responded dramatically. The study suggests that these non-sun-exposed melanomas may be more susceptible to targeted treatments.
A new Cleveland Clinic study emphasizes the significance of prompt treatment in stage I melanoma, with patients treated within 30 days showing better survival rates. Delayed treatment beyond 90 days led to significantly worse outcomes, especially among older patients and those with comorbidities.
Researchers found a strong association between certain beneficial gut bacteria and improved response to immunotherapies in patients with metastatic melanoma. The beneficial bacteria, including three specific species, were found to prime the immune system to attack cancer cells more effectively.
A study found that Medicaid patients experienced surgical treatment delays more frequently than those with private insurance for melanoma surgeries. Non-white patients and those without dermatologist referrals also faced longer wait times.
A new study found that delays in melanoma surgery are common among Medicaid and privately insured patients, highlighting the need for better access to specialty care. The likelihood of surgical delay decreased when dermatologists performed operations or made diagnoses.
A study using temporary tattoos helped medical students develop a greater understanding of skin cancer and empathy for patients. The study found that wearing a realistic tattoo provided a powerful experience, allowing students to consider the person behind the illness.
A recent study published in the Journal of Health Communication found that illustrations are more effective than photos in helping people spot problematic moles during skin self-examinations. The research uses eye-tracking technology to show that participants fixate on atypical moles longer with illustrated visuals, leading to increase...
The COMBI-AD trial found that combination dabrafenib and trametinib therapy doubled relapse-free survival in stage III BRAF-mutant melanoma patients. The treatment was also shown to improve overall survival, distant metastases-free survival, and freedom from relapse.
The CheckMate 238 trial demonstrated that adjuvant nivolumab is superior to standard of care ipilimumab in patients with high-risk stage III/IV melanoma, resulting in improved relapse-free survival and reduced side effects. Nivolumab's benefits were observed across various patient subgroups.
Researchers from Boston University School of Medicine discovered that enhancing palmitoylation in the variant MC1R protein of redheads can reduce cancer risk for melanoma. This finding offers a potential alternative strategy to prevention by reducing sun exposure, which has been the focus of public health work.
Early FDG-PET/CT scanning can accurately predict melanoma patients' response to immune checkpoint inhibitor therapy, providing a more effective treatment approach. The study developed criteria with high sensitivity, specificity, and accuracy, identifying a small increase in tumor uptake as an indication of responsiveness.
Researchers developed an AI system to analyze skin lesion images and detect melanoma biomarkers, reducing unnecessary biopsies and improving early detection of deadly skin cancer. The technology provides objective data on eumelanin and hemoglobin levels, helping doctors rule out melanoma before invasive action.
A recent study published in JAMA Dermatology identified key features linked to amelanotic melanoma, including the absence of moles on the back, multiple freckles, and sun-sensitive traits. These characteristics may trigger doctors and patients to pay attention to pink spots that could be indicative of this type of skin cancer.
A new study found that sharing personalized melanoma genomic risk information with relatives and friends can lead to increased discussions about skin cancer prevention. The study suggests that this process could encourage healthy behavior change within families.
A study found that kidney transplant recipients have a higher incidence of melanoma compared to the general population, with risk factors including older age, male sex, and white ethnicity. Long-term immunosuppressive therapy contributes to this increased risk.
The University of Sussex is conducting vital skin cancer research with a new £428K grant. The project focuses on targeting the PHIP(2) protein, which is present in high amounts in melanoma and other aggressive cancers.
A new international study involving 3,500 patients found that removing all lymph nodes in the area closest to the melanoma may not provide a significant survival advantage. The study suggests that patients can be spared from complications and repeat hospitalizations if only their sentinel lymph node is removed.
Researchers found that patients with Parkinson's were four times more likely to have a history of melanoma than those without the disease. In contrast, people with melanoma had a fourfold higher risk of developing Parkinson's. The study suggests that common environmental or genetic factors may underlie both conditions.
A study of US pathologists reveals that melanoma diagnoses can be inaccurate and non-reproducible, particularly in the middle of the disease spectrum. The results suggest that only cases at the polar ends of the spectrum are accurately diagnosed.
Researchers at CNIO have developed a technique to study melanoma progression in mice, revealing unknown mechanisms and identifying new markers of metastasis. The MIDKINE protein has been identified as a key factor in melanoma metastasis, representing a new therapeutic target.
A new analysis found that delaying lymph node biopsy more than 30 days after melanoma diagnosis does not adversely affect long-term clinical outcomes. The study examined 2,483 patients and found similar results in disease-free survival and melanoma-specific survival.
New research from Swiss Tropical and Public Health Institute finds that radon increases the risk of developing malignant skin cancer, with a 50% increase in risk for 30-year-olds. The study highlights the importance of reducing residential radon exposure through appropriate house construction.
A major new study published in The New England Journal of Medicine found that completion lymph node dissection, a procedure to remove all lymph nodes near the original tumor, does not increase overall survival rates for melanoma patients. However, it can help gauge cancer spread and disease-free time.
A new robot technology reveals that the ADAM10 signalling pathway is activated during melanoma transformation, enabling a better diagnosis and potential simplification of detection methods. The research suggests avoiding cosmetic products with aluminium, which can activate this pathway.
A CNIO researcher has been funded by the Melanoma Research Alliance to study brain metastasis in melanoma, focusing on blocking cancer cell spread by targeting the microenvironment. The goal is to develop a new concept of treating metastasis in personalized medicine.
Researchers analyzed data from large-scale studies of erectile dysfunction medication users and found an overall 11% increase in melanoma risk. However, they attribute the increased risk to detection bias rather than a direct cause-and-effect link between medications and melanoma.
Researchers have discovered that FES, a protein previously linked to cancer development, actually acts as a tumor suppressor in melanoma. The study found that restoring FES expression through epigenetic drugs may provide a novel therapeutic strategy against melanoma.
The Melanoma Research Alliance awarded Dr. Neville Sanjana a grant to use CRISPR technology to identify genetic mutations causing immunotherapy resistance in melanoma. The goal is to create a list of actionable mutations for patients enrolled in melanoma immunotherapy trials.
Researchers analyzed data on 2,025 women diagnosed with stage I to IV melanoma and found no significant differences in prognosis between pregnant and non-pregnant patients. The study upends long-held beliefs about pregnancy and melanoma, showing that screening and treatment should be similar for both groups.
Researchers found significant evidence that inhibiting protein TERT may aid in diagnosis and treatment of acral lentiginous melanoma (ALM). In laboratory experiments, over 75% of ALM cancer cells were affected by a drug that inhibits TERT.
The article reviews current screening practice for melanoma in the US, highlighting risk groups and proposing full screening recommendations. The authors critically assess the USPSTF's 2016 Draft Recommendation Statement and propose evidence-based guidelines for screenings.
Researchers have identified mutations in the SF3B1 gene present in 37% of mucosal melanoma samples, which could lead to novel therapies. The study highlights the potential of targeting this gene in patients with advanced mucosal melanoma.
A gene variant that produces red hair and fair skin in humans and mice has been found to contribute to the association between melanoma and Parkinson's disease. The study shows that mice carrying this variant have reduced dopamine production and increased sensitivity to toxins, making them more susceptible to neurodegeneration.
A study found that while melanoma survivors limit sun exposure, some still seek out tans and get sunburns. Survivors reported suboptimal behaviors, with 20% getting sunburned in the previous year.
Researchers found that loss of tumor-suppressing genes, not mutations, leads to resistance to immune checkpoint blockade drugs in melanoma. Anti-CTLA4 treatment can prime T cells for anti-PD1 therapy, improving patient response.
Researchers have successfully imaged the two dominant melanin molecules using a refined Raman-based technique, CARS microscopy. This breakthrough could lead to new understandings and early detection of melanoma, particularly in cases where pheomelanin is present.
A study published in The Journal of the American Osteopathic Association found that young adults with high melanin content skin are at increased risk of sunburn. Researchers suggest that targeted sunburn prevention programs, including apps that gamify protection, could help reduce this risk.
Scientists at The Wistar Institute have identified an anti-aging gene that inhibits a protein involved in metastatic progression and resistance to targeted therapies. Activating this gene with an anti-diabetic drug may provide a promising adjuvant therapy for older melanoma patients.
A study found that patients with metastatic melanoma who responded to PD1 checkpoint inhibitor therapy had a greater diversity of gut bacteria and larger volumes of specific bacteria than non-responders. The researchers also discovered increased immune infiltrates in responders' tumors, correlated to the abundance of a specific bacterium.
Researchers analyzed data from over 580 patients with stage II melanoma and found that 40% of recurrences were spotted by patients due to suspicious skin changes or other symptoms. Patients are encouraged to regularly examine their skin and report any new or unusual symptoms to their physicians.
Researchers predict that melanoma death rates will decrease by 2050 due to the aging of populations, but the number of deaths may increase. Effective treatments could lead to a further decline in mortality rates.
A new immunotherapy, pembrolizumab, has shown significant activity against mucosal melanoma tumors and prolonged survival in patients with bladder cancer. The treatment demonstrated a response rate of 16% and improved overall survival rates compared to chemotherapy.
According to the study, 11 of the 49 states with reported melanoma incidence rates saw a decrease, while 38 states experienced an increase. The researchers suggest that better treatment may be prolonging the life of patients with melanoma.
A new study reports an estimated 76,380 Americans will be diagnosed with melanoma in 2016, with current lifetime risk being 1 in 54 for invasive melanoma. The overall burden of disease is increasing, with rising rates and higher mortality rates, exceeding the previous estimate of 10,130 deaths
Research finds that pembrolizumab is a cost-effective first-line treatment for advanced melanoma, offering improved survival and progression-free rates compared to ipilimumab and cytotoxic chemotherapy. The study suggests that healthcare authorities should consider including pembrolizumab as a reimbursable item in the public setting.
Research at McGill University has identified a link between decreased X chromosome gene PPP2R3B expression and tumor progression in melanoma. The findings suggest that genetic specificity of the X chromosome plays a role in gender differences observed in melanoma prognosis.
A Northwestern Medicine study shows that trained partners can catch far more mole irregularities than control group participants, growing their confidence and trust along the way. Common areas prone to developing fatal melanoma include hard-to-see spots on the body.
Recent developments in dendritic cell vaccines and oncolytic immunotherapy have led to improved outcomes in melanoma patients. Various vaccine candidates are being developed and tested in clinical trials, offering new avenues for treating this malignancy.
Researchers at LSU Health New Orleans report a complete response in a patient with long history of melanoma after treatment with a combination of an interferon and melanoma vaccine. The FDA has approved a first-of-its-kind therapy, talimogene laherparepvec, which shows a 10.8% complete response rate.
A study published in Cancer Epidemiology, Biomarkers & Prevention found that alcohol intake is associated with a higher risk of invasive melanoma, especially among individuals who consume more than 20 grams of alcohol per day. White wine was the most clearly associated with increased risk.
A Penn study found that decreased levels of the gene p15 can distinguish nevi from melanomas. The protein p15 inhibits nevus cell proliferation and can be used as a biomarker to identify borderline cases.
A study published in JAMA Dermatology found that patients with a family history of melanoma, multiple primary melanomas, or many moles are at higher risk for developing melanoma. The researchers recommend tailoring surveillance programs to individual risk factors to improve early detection and treatment.
A new study suggests that identifying patients with higher risk factors, such as many moles or family history of melanoma, can improve the identification and treatment of those at higher risk. The study found that these patients were more likely to have melanoma on specific areas of their skin.
A study by the University of Texas MD Anderson Cancer Center found that 81% of indoor tanning facilities complied with the Texas ban on indoor tanning for those under 18. The study also showed that daily use practices exceeded FDA guidelines, and most facilities indicated that burns are possible with indoor tanning.
Researchers found a combination of immunotherapy options improves overall survival and lowers the risk of life-threatening events in late-stage melanoma patients. PD-1 inhibitors were associated with the lowest risk of life-threatening events, making them a promising first-line therapy option.
A phase III trial found ipilimumab as adjuvant therapy significantly improved overall survival in patients with high-risk stage III melanoma, reducing relative risk of death by 28% at 5.3 years median follow-up.
A survey found that over 5,000 metastatic melanoma patients in Europe are denied access to innovative treatments annually. The inequality affects Eastern and South-Eastern European countries more severely, where only 10% of patients have access to the latest treatment recommended by current guidelines.
A survey by Dr Lidija Kandolf-Sekulovic found that over 5000 European melanoma patients are denied access to innovative treatments each year. In Eastern Europe, only 42% of countries have registered the treatment, and only 18% have full reimbursement coverage.